Anti-PCSK9 (Alirocumab), Human IgG1 Antibody

Datasheet
Specifications
Clonality: Monoclonal
Host: Recombinant
Reactivity: Human
Additional Information
Synonyms: REGN727, SAR-236553, FH3, PC9, FHCL3, NARC1, LDLCQ1, NARC-1, HCHOLA3
UniProt ID: DB09302

Immunogen

Human PCSK9

Background

The research-grade biosimilar antibody is a fully human IgG1 monoclonal antibody that binds to and inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), an enzyme that has ""gain-of-function"" mutations in autosomal dominant hypercholesterolemia. PCSK9 is secreted by the liver and binds to the LDL receptors in serum and marks them for lysosomal degradation. As a result, the LDL receptors are unable to recycle to the plasma membrane, thus reducing their binding to LDL-C and subsequent clearance of LDL-C from plasma. Therefore, by binding to free PCSK9, the biosimilar allows more LDL-C reuptake by the liver and facilitates a higher rate of clearance of LDL-C. The original drug received approval from the FDA as a second-line of treatment for heterozygous familial hypercholesterolemia in adults, whose LDL-C was not controlled by the combination of diet and statin treatment.

  • Catalog Number
    A2153-100-BV
  • Supplier
    BioVision
  • Size
  • Shipping
    Blue Ice
  • Price
  • 555,00 €
Add to Cart
you need any help?

Please contact:

Dr. Monika Haas

Tel. +49 (0) 6221 71415 16 info@biocat.com